These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23731618)

  • 1. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
    Veillette A; Guo H
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elotuzumab for the treatment of multiple myeloma.
    Moreau P; Touzeau C
    Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
    Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
    Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
    Lonial S
    Cancer J; 2016; 22(1):3-6. PubMed ID: 26841009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
    Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
    Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.
    Kim JR; Mathew SO; Mathew PA
    Immunobiology; 2016 Jan; 221(1):31-9. PubMed ID: 26310579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of elotuzumab and its potential in the treatment of multiple myeloma.
    Liu YC; Szmania S; van Rhee F
    Blood Lymphat Cancer; 2014 Jun; 2014(4):15-27. PubMed ID: 26005365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
    van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
    Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
    Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
    Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
    Malaer JD; Mathew PA
    Am J Cancer Res; 2017; 7(8):1637-1641. PubMed ID: 28861320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
    Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
    Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Laubach J; Richardson P
    Expert Opin Biol Ther; 2013 Dec; 13(12):1731-40. PubMed ID: 24151843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CS1-directed monoclonal antibody therapy for multiple myeloma.
    Benson DM; Byrd JC
    J Clin Oncol; 2012 Jun; 30(16):2013-5. PubMed ID: 22547601
    [No Abstract]   [Full Text] [Related]  

  • 19. 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer.
    Malaer JD; Marrufo AM; Mathew PA
    Clin Immunol; 2019 Jul; 204():50-56. PubMed ID: 30347240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma.
    Ishibashi M; Morita R; Tamura H
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33451089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.